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Abstract
The recent identification of the CARD15/NOD2 gene as a
susceptibility locus for Crohn’s disease represents an
important step towards the delineation of the immuno-
pathogenesis of inflammatory bowel disease. CARD15
functions as an intracellular receptor for bacterial com-
ponents and thus represents an important link between
inflammatory bowel disease and innate immunity. Three
major CARD15/NOD2 gene mutations have been associ-
ated with Crohn’s disease in Caucasians in several inde-
pendent studies. Together, they explain about 20% of the
genetic susceptibility for Crohn’s disease. Genotype-
phenotype analyses demonstrated an association of
these mutations with ileum-specific disease, an in-
creased incidence of the fibrostenotic phenotype and an
earlier age of disease onset. Beside these associations,
no other relationship between the CARD15/NOD2 geno-
type and disease behavior or response to treatment has
been detailed so far. Thus, the clinical impact of knowing
the patient’s genotype is limited at this time. Screening
for CARD15 mutations in order to identify high-risk indi-
viduals or to introduce an individualized disease man-
agement is therefore currently not recommended.
Copyright © 2003 S. Karger AG, Basel
Introduction
The current hypothesis for the pathogenesis of chronic
inflammatory bowel disease comprises a loss of tolerance
towards luminal antigens in a genetically susceptible host
resulting in a chronic, spontaneously relapsing inflamma-
tion.
Several lines of evidence are compatible with a signifi-
cant role of genetic factors in inflammatory bowel disease,
especially in Crohn’s disease. The most striking example
is provided by twin studies, which report concordance
rates for Crohn’s disease between 42 and 58% in monozy-
gotic twins [1–4], whereas in dizygotic twins concordance
is not significantly enhanced. Epidemiological studies
demonstrate a familial aggregation with approximately 5–
10% of all affected individuals reporting a positive famil-
ial history of inflammatory bowel disease [5–7]. The rela-
tive risk for first degree relatives of patients with Crohn’s
disease is estimated to be about 15-fold increased when
compared to the general population [8, 9]. Ethnic differ-
ences in the prevalence of the disease further underline
the significant role of genetic susceptibility. The highest
prevalence rates are reported for Ashkenazi Jews. In Afri-
can-Americans the rates are lower than in Caucasians,
and in Asians the lowest rates have been observed [10–
15].
For several years, considerable efforts aimed at the
identification of the genetic background of inflammatory
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Fig. 1. Structural domains of the CARD15 protein. Like most of the members of the NOD
family, CARD15 contains three distinct functional domains: a centrally located nucleotide-
binding domain, an amino-terminal effector-binding domain [in the case of CARD15 the two
caspase-recruitment domains (CARD)] and a carboxy-terminal ligand-recognition domain
[the leucine-rich repeats (LRR)]. The location of the three Crohn’s disease-associated variants
within the protein are indicated by arrows.
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bowel disease. Two complementary approaches, namely
genetic linkage analysis and the search for candidate
genes, led to the identification of a number of susceptibili-
ty loci and to the postulation of functional candidate
genes with a presumptive role in immune regulation. The
first real breakthrough, however, was achieved only two
years ago with the identification of the CARD15/NOD2
gene as the first susceptibility gene with a consistent asso-
ciation with Crohn’s disease.
Alterations of the CARD15/NOD2 Gene and
Crohn’s Disease
In May 2001, two research groups reported indepen-
dently that Crohn’s disease is associated with mutations
in the NOD2 gene, which was later renamed CARD15
[16, 17]. This association has been confirmed by numer-
ous other studies [18–28].
The CARD15 gene is located in the pericentromeric
region of chromosome 16 inside the susceptibility locus
displaying the strongest linkage with Crohn’s disease [29,
30], namely the IBD1 locus. It encodes a 1,040-amino-
acid protein containing several functional domains: two
N-terminal caspase activation and recruitment domains
(CARDs), a centrally located nucleotide binding domain
(NBD) and a C-terminal leucine-rich repeat domain
(LRR) (fig. 1) [31]. Functional studies demonstrated that
CARD15 is one of the numerous pattern-recognition
receptors implicated in the intracellular sensing of bacte-
rial components [31].
Crohn’s Disease-Associated CARD15 Genetic Variants
Three common variants of CARD15 have been linked
to the development of Crohn’s disease. The most com-
mon genetic defect is the frameshift mutation 1007fs
(3020insC) in exon 11, resulting in a premature stop
codon and thus in a truncated CARD15 protein. The two
other missense mutations are located in exons 4 and 8 and
lead to amino acid substitutions Arg702Trp and
Gly908Arg, respectively. These three mutations are lo-
cated in the leucine-rich repeat domain of the CARD15
protein or in its vicinity (fig. 1) and occur on the back-
ground of the most common variant Pro268Ser.
Approximately 30% of Crohn’s disease patients carry
one and up to 17% carry two mutated CARD15/NOD2
risk alleles [32]. The allele frequencies reported for
Crohn’s disease and control populations in a variety of
studies are depicted in table 1. The three above men-
tioned CARD15 variants seem to confer an increased risk
for Crohn’s disease only in Caucasians, as these mutations
were not detected in populations with a different ethnic
background, e.g. in Japanese [33–35], Korean [36] or Chi-
nese [37]. A study in African-Americans with Crohn’s dis-
ease also reported lower carriage rates of these alleles and
the presence of uncommon variants such as Arg790Gln
[38]. Among Caucasians, ethnic differences in the allele
frequencies have also been reported. Jewish patients have
a higher frequency of the Gly908Arg allele and a lower
frequency of the Arg702Trp allele, when compared to
non-Jewish Crohn’s disease patients [26]. The allele fre-
quencies in familial and sporadic Crohn’s disease were
comparable in two Caucasian cohorts [19, 24], whereas in
a population of Ashkenazi Jews, familial cases displayed a
significantly higher frequency of the Gly908Arg variant
than sporadic cases [39].
Having one copy of a mutated CARD15/NOD2 allele
confers a 2- to 4-fold increased risk of developing Crohn’s
disease, whereas having two mutated copies in homozy-
gous or compound heterozygous form increases the risk
20- to 40-fold [16–18]. However, homozygosity for mu-
tant CARD15/NOD2 has also been observed in healthy
CARD15/NOD2 Mutations in Crohn’s
Disease
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Fig. 2. Schematic representation of CARD15
function. Similar to Toll-like receptors on the
cell surface, CARD15 functions as a receptor
for pathogen-associated molecular patterns
(PAMPs) in the cytosol. Recognition of mura-
myl dipeptide (MDP) derived from bacterial
peptidoglycan through the leucin-rich region
of CARD15 results in activation of nuclear
factor NF-ÎB and subsequent initiation of an
inflammatory response.
Table 1. Allele frequencies of Crohn’s disease-associated CARD15/NOD2 mutations in different studies (% values)
References Population CARD15/NOD2 mutations
1007fs
Crohn’s disease vs.
(controls)
Gly908Arg
Crohn’s disease vs.
(controls)
Arg702Trp
Crohn’s disease vs.
(controls)
Hugot et al. [16] European 12 (2) 6 (1) 11 (4)
Hampe et al. [18] German/British 16 (4.4) not determined not determined
Lesage et al. [19] European 11 (2) 6 (1) 11 (4)
Ahmad et al. [20] British 9.4 (1.6) 3.3 (1.4) 12.5 (5.2)
Cuthbert et al. [21] European 12 (2) 6 (1) 11 (4)
Vavassori et al. [22] Italian 11.6 (1.2) not determined not determined
Murillo et al. [23] Dutch 8.5 (1) 4.3 (3) not determined
Vermeire et al. [24] Canadian 10.3 (0.7) 5.2 (0.7) 12.9 (4.2)
Radlmayr et al. [25] German 14 (1.66) not determined not determined
Bonen et al. [26] US Caucasians 8.4 (4) 4.3 (1.7) 10.8 (4)
Cavanaugh et al. [30] Australian 7 (0) 2 (1) 11 (5)
controls [40]. These data suggest that loss-of-function mu-
tations in the CARD15/NOD2 gene are neither necessary
nor sufficient for developing Crohn’s disease, and that
other genetic factors as well as environmental influences
are needed for disease manifestation.
Role of CARD15: Link between Genetic Susceptibility
and Environmental Factors (e.g. Bacterial Flora)
The CARD15 protein is located in the cytosol and is
now recognized as a member of a family of proteins which
are involved in intracellular recognition of bacterial com-
ponents (fig. 2) [41–42]. Although the expression of
CARD15 was reported to be restricted to peripheral blood
monocytes [31], recent studies have shown basic expres-
sion in granulocytes and dendritic cells [43] as well as in
several colonic epithelial cell lines and primary intestinal
epithelial cells [44]. Moreover, elevated amounts of
CARD15 were found in primary colonic epithelial cells
[45, 46] and in particular in Paneth cells [47] from
patients with inflammatory bowel disease. The expression
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of CARD15 can be enhanced by proinflammatory cyto-
kines and bacterial components via Nuclear Factor (NF)-
ÎB activation [43, 45].
Functional studies in human embryonic kidney (HEK)
293T cells transfected with CARD15 revealed that the
wild-type protein mediates responsiveness to lipopolysac-
charide (LPS) and peptidoglycan (PGN) preparations
from several bacteria [17, 26, 31, 48]. Recent works iden-
tified muramyl dipeptide (MDP), the minimal essential
structure of bacterial peptidoglycan, as the moiety specifi-
cally recognised by CARD15 [49, 50]. The three major
Crohn’s disease-associated variants are defective in their
ability to activate NF-ÎB in response to MDP [17, 26].
Especially the truncated CARD15 protein, which arises
from the 1007fs mutation, completely lacks this activity
[17, 49, 50]. These results were obtained in transfected
cells and were subsequently verified by assessment of
mRNA expression and protein synthesis of pro- and anti-
inflammatory cytokines in peripheral blood monocytes
from individuals carrying different CARD15 variants
[49, Török et al., unpubl. data].
At present, it is not clear how CARD15/NOD2 muta-
tions and the ensuing decreased NF-ÎB activation confer
susceptibility to Crohn’s disease. Assuming that CARD15
is a pattern-recognition receptor, it seems possible that the
mutations result in an inadequate innate immune re-
sponse, e.g. a defective activation of monocytes-macro-
phages in response to intestinal microbes. This disturbed
response could be associated with impaired killing of
intracellular microbes resulting in compensatory increase
of other components of the immune system such as a
marked effector T cell response [51]. On the other hand,
the absence of functional CARD15 in epithelial cells
could lead to an impaired secretion of chemokines and
defensins in response to microbial products followed by a
proliferation of bacteria in the crypts and a loss of barrier
function of the mucosa. Several observations support this
hypotheses. Hisamatsu et al. [44] showed that CARD15
functions as an antibacterial factor in human intestinal
epithelial cells by constraining intracellular bacterial sur-
vival and that the 1007fs mutant lacks this activity. More-
over, a recent communication by Wehkamp et al. [52]
reported an impaired expression of antibacterial peptides
(defensins) in epithelial cells from Crohn’s disease pa-
tients carrying CARD15/NOD2 mutations.
The identification of CARD15/NOD2 as a susceptibil-
ity locus for Crohn’s disease confirms at the molecular
level that an inappropriate activation of the mucosal
immune system by the intestinal flora plays a causal role
in the development of Crohn’s disease. Thus, this associa-
tion confers an important link between inflammatory
bowel disease and innate immunity [53].
Clinical Implications
Among the cases classified as Crohn’s disease, differ-
ent clinical phenotypes with regard to disease location,
extent, aggressiveness, behavior, local and systemic com-
plications as well as varying responses to medical therapy
have been described [54]. The observation of conserved
phenotypes in multiplex Crohn’s disease families [55, 56]
is compatible with the assumption that the genetic back-
ground influences the phenotype.
Following the identification of CARD15/NOD2 as a
susceptibility gene for Crohn’s disease, many questions
were raised regarding the importance of this discovery for
the daily clinical practice. Could mutations in this gene
determine the natural history of Crohn’s disease? Is the
CARD15/NOD2 genotype associated with a specific phe-
notype, a specific location, extent or aggressiveness of the
disease? Can it predict the response to a specific thera-
peutic agent? Is there a diagnostic role for the mutations?
Should we perform screening for CARD15/NOD2 mu-
tants in the general population, in the groups at risk, or in
Crohn’s disease patients before initiating a specific thera-
py? Only a few of these questions can be answered satis-
factorily at present.
CARD15/NOD2 Genotype and Clinical Course of
Crohn’s Disease
Several studies about the relationship between
CARD15/NOD2 mutations and the clinical presentation
of Crohn’s disease have been published. The only consis-
tent finding concerns the disease location, as a number of
studies reported a significant association between carriage
of one or more CARD15/NOD2 risk alleles and ileal dis-
ease. Ahmad and colleagues [20] performed genotype-
phenotype analysis in 244 extensively characterized
Crohn’s disease patients with a median follow-up of 16
years. The results demonstrated that CARD15/NOD2
mutations determine ileal disease. Among 429 patients
analyzed in a large European study, the frequency of
CARD15 mutations was significantly increased in ileum-
specific disease, when compared with colon-specific dis-
ease (26.9 vs. 12.7%, p = 0.0004) [21]. In a French study
comprising 166 sporadic and 287 familial cases of
Crohn’s disease, the patients carrying two risk alleles were
characterized by a less frequent colonic involvement than
wild-type patients (p = 0.003) [19]. The predominance of
CARD15/NOD2 Mutations in Crohn’s
Disease
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ileal disease in patients carrying mutations in CARD15
was also reported in other studies [24, 57, 58]. Important-
ly, the association with disease location (ileal and right
colonic disease) was the only one also confirmed in a pro-
spective cohort study, in which 106 German and 55 Nor-
wegian patients with Crohn’s disease were enrolled [57].
Data concerning disease behavior are more inconsis-
tent. Reasons could be the use of different definitions for
the classification as well as the fact that disease behavior
changes through time, which underscores the need for
long observation periods and illustrates the inherent diffi-
culties of retrospectively differentiating clinical subtypes.
Some groups reported an association with the fibrostenot-
ic phenotype [19, 25, 57–59], the presence of fistulas [25,
57–59] or the need for surgery [25, 58], whereas others did
not confirm such findings [20, 60].
An earlier age of disease onset in patients carrying two
CARD15/NOD2 risk alleles in homozygous or compound
heterozygous form has also been reported [19, 20, 61].
Onset of disease occurred approximately 2 years earlier in
these patients, when compared with all Crohn’s disease
patients.
CARD15 and Response to Treatment
At this time little is known about the influence of
CARD15 genotype on the response to medical therapy
in Crohn’s disease. Vermeire et al. [62] studied the
CARD15/NOD2 genotype in 245 patients with Crohn’s
disease receiving therapy with anti TNF-alpha antibodies
(infliximab) and observed no relationship between the
presence of mutations and short-term response or re-
sponse duration. Moreover, the authors could not identify
any clinical characteristic which, in combination with
CARD15/NOD2 mutations, modified the response to
treatment. Similarly, Mascheretti et al. [63] reported no
association between the response to infliximab and the
CARD15 variants in two independent cohorts of 90 and
444 patients with Crohn’s disease. These negative find-
ings exclude the three CARD15 mutants as a predictive
factor for therapeutic response to infliximab. However,
data concerning other therapeutic approaches, such as
glucocorticoids, aminosalicylates or immunosuppressors,
are lacking so far.
Screening for CARD15/NOD2 Variants?
One of the major questions raised is whether screening
for CARD15/NOD2 genotype in the population at risk or
in patients already diagnosed with Crohn’s disease should
be introduced into the clinical practice.
Giving the limited penetrance and the lack of consis-
tent information about the positive and negative predic-
tive values of genotypes in unaffected relatives (the major
risk group), a screening for CARD15/NOD2 variants is
currently not recommended. The majority of high-risk
individuals will not develop Crohn’s disease, as studies in
twin siblings demonstrated [64]. Moreover, even if high-
risk individuals are detected by genotyping, there are at
present no efficient prophylactic methods that could pre-
vent disease onset. Thus, the diagnostic role of CARD15/
NOD2 genotyping is limited. It was suggested that muta-
tion analysis will help to classify undifferentiated colitis
cases. However, the low frequency of CARD15/NOD2
mutations in Crohn’s disease patients with an ulcerative
colitis-like phenotype limits this clinical application [53].
Recommending genotyping in patients already diag-
nosed with Crohn’s disease is also premature. Data about
the influence of the genotype on disease behavior are
inconsistent and large prospective studies are needed to
determine whether mutations in CARD15/NOD2 can
predict the prognosis of Crohn’s disease, e.g. a more
aggressive disease course with need of early immunosup-
pressive therapy.
In addition, the lack of data regarding the association
between CARD15 variants and specific therapeutic re-
sponses currently disables the possibility of individual-
ised, genotype-based therapies.
Conclusions
The association of CARD15/NOD2 mutations with
Crohn’s disease opens up a new era in the history of
inflammatory bowel disease. It shows how the two com-
plementary approaches, linkage analysis and the study of
candidate genes can be successfully used in the identifica-
tion of disease susceptibility genes. The role of CARD15
as a pattern recognition receptor and the loss of function
of the genetic variants associated with Crohn’s disease
establishes a link between innate immunity and chronic
bowel inflammation and confirms the pathogenetic im-
portance of luminal bacteria. Moreover, these data are
compatible with an immunodeficiency of the mucosal
immune system as a pivotal first step in the pathogenesis
of Crohn’s disease [65]. Although the discoveries are
important for understanding the etiology of Crohn’s dis-
ease, at this time, they have only a modest role in clinical
practice. Further studies are needed to clarify the geno-
type-phenotype relationships and the role of genetic test-
ing in predicting disease behavior. A better understanding
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of the pathophysiologic mechanisms could lead to the
development of new prophylactic and therapeutic strate-
gies and to an individualized manner of their application.
In case these prophylactic and therapeutic goals are
reached, genetic testing for identifying high risk individu-
als and for predicting response to specific therapies will
constitute an important new diagnostic tool for clini-
cians.
References
1 Tysk C, Lindberg E, Jarnerot G, Floderus-
Myrhed B: Ulcerative colitis and Crohn’s dis-
ease in an unselected population of monozygot-
ic and dizygotic twins: A study of heritability
and the influence of smoking. Gut 1988;29:
990–996.
2 Thompson NP, Driscoll R, Pounder RE,
Wakefield AJ: Genetics versus environment in
inflammatory bowel disease: Results of a Brit-
ish twin study. BMJ 1996;312:95–96.
3 Subhani J, Montgomery SM, Ounder RE,
Wakefield AJ: Concordance rates of twins and
siblings in inflammatory bowel disease. Gut
1998;42:A40.
4 Halfvarson J, Bodin L, Tysk C, Lindberg E,
Jarnerot G: Inflammatory bowel disease in a
Swedish twin cohort: A long-term follow-up of
concordance and clinical characteristics. Gas-
troenterology 2003;124:1767–1773.
5 Farmer RG, Michener WM, Mortimer EA:
Studies of family history among patients with
inflammatory bowel disease. Clin Gastroenter-
ol 1980;9:271–277.
6 Monsen U, Bernell O, Johansson C, Hellers G:
Prevalence of inflammatory bowel disease
among relatives of patients with Crohn’s dis-
ease. Scand J Gastroenterol 1991;26:302–306.
7 Russel MG, Pastoor CJ, Janssen KM, van
Deursen CT, Muris JW, van Wijlick EH,
Stockbrugger RW: Familial aggregation of in-
flammatory bowel disease: A population-based
study in South Limburg, The Netherlands. The
South Limburg IBD Study Group. Scand J
Gastroenterol Suppl 1997;223:88–91.
8 Orholm M, Munkholm P, Langholz E, Nielsen
OH, Sorensen IA, Binder V: Familial occur-
rence of inflammatory bowel disease. N Engl J
Med 1991;324:84–88.
9 Peeters M, Nevens H, Baert F, Hiele M, de
Meyer AM, Vlietinck R, Rutgeerts P: Familial
aggregation in Crohn’s disease: Increased age-
adjusted risk and concordance in clinical char-
acteristics. Gastroenterology 1996;111:597–
603.
10 Sonnenberg A, Wasserman ICH: Epidemiology
of inflammatory bowel disease among US mili-
tary veterans. Gastroenterology 1991;101:122–
130.
11 Kurata JH, Kantor-Fish S, Frankl H, Godby P,
Vadheim CM: Crohn’s disease among ethnic
groups in a large health maintenance organiza-
tion. Gastroenterology 1992;102:1940–1948.
12 Ogunbi SO, Ransom JA, Sullivan K, Schoen
BT, Gold BD: Inflammatory bowel disease in
African-American children living in Georgia. J
Pediatr 1998;133:103–107.
13 Yang SK, Loftus EV Jr, Sandborn WJ: Epide-
miology of inflammatory bowel disease in Asia.
Inflamm Bowel Dis 2001;7:260–270.
14 Roth MP, Petersen GM, McElree C, Vadheim
CM, Panish JF, Rotter JI: Familial empiric risk
estimates of inflammatory bowel disease in
Ashkenazi Jews. Gastroenterology 1989;96:
1016–1020.
15 Yang H, Taylor KD, Rotter JI: Inflammatory
bowel disease. I. Genetic epidemiology. Mol
Genet Metab 2001;74:1–21.
16 Hugot JP, Chamaillard M, Zouali H, Lesage S,
Cezard JP, Belaiche J, Almer S, Tysk C, O’Mo-
rain CA, Gassull M, Binder V, Finkel Y, Cortot
A, Modigliani R, Laurent-Puig P, Gower-Rous-
seau C, Macry J, Colombel JF, Sahbatou M,
Thomas G: Association of NOD2 leucine-rich
repeat variants with susceptibility to Crohn’s
disease. Nature 2001;411:599–603.
17 Ogura Y, Bonen DK, Inohara N, Nicolae DL,
Chen FF, Ramos R, Britton H, Moran T, Ka-
raliuskas R, Duerr RH, Achkar JP, Brant SR,
Bayless TM, Kirschner BS, Hanauer SB, Nu-
nez G, Cho JH: A frameshift mutation in
NOD2 associated with susceptibility to
Crohn’s disease. Nature 2001;411:603–606.
18 Hampe J, Cuthbert A, Croucher PJ, Mirza
MM, Mascheretti S, Fisher S, Frenzel H, King
K, Hasselmeyer A, MacPherson AJ, Bridger S,
van Deventer S, Forbes A, Nikolaus S, Len-
nard-Jones JE, Foelsch UR, Krawczak M,
Lewis C, Schreiber S, Mathew CG; Association
between insertion mutation in NOD2 gene and
Crohn’s disease in German and British popula-
tions. Lancet 2001;357:1925–1928.
19 Lesage S, Zouali H, Cezard JP, Colombel JF,
Belaiche J, Almer S, Tysk C, O’Morain C, Gas-
sull M, Binder V, Finkel Y, Modigliani R,
Gower-Rousseau C, Macry J, Merlin F, Cha-
maillard M, Jannot AS, Thomas G, Hugot
JP; EPWG-IBD Group; EPIMAD Group;
GETAID Group: CARD15/NOD2 mutational
analysis and genotype-phenotype correlation in
612 patients with inflammatory bowel disease.
Am J Hum Genet 2002;70:845–857. 
20 Ahmad T, Armuzzi A, Bunce M, Mulcahy-
Hawes K, Marshall SE, Orchard TR, Craw-
shaw J, Large O, de Silva A, Cook JT, Barnardo
M, Cullen S, Welsh KI, Jewell DP: The molecu-
lar classification of the clinical manifestations
of Crohn’s disease. Gastroenterology 2002;122:
854–866.
21 Cuthbert AP, Fisher SA, Mirza MM, King K,
Hampe J, Croucher PJ, Mascheretti S, Sander-
son J, Forbes A, Mansfield J, Schreiber S,
Lewis CM, Mathew CG: The contribution of
NOD2 gene mutations to the risk and site of
disease in inflammatory bowel disease. Gastro-
enterology 2002;122:867–874.
22 Vavassori P, Borgiani P, D’Apice MR, De Ne-
gris F, Del Vecchio Blanco G, Monteleone I,
Biancone L, Novelli G, Pallone E: 3020insC
mutation within the NOD2 gene in Crohn’s
disease: Frequency and association with clini-
cal pattern in an Italian population. Dig Liver
Dis: 2002;34:153.
23 Murillo L, Crusius JB, van Bodegraven AA,
Alizadeh BZ, Pena AS: CARD15 gene and the
classification of Crohn’s disease. Immunoge-
netics 2002;54:59–61.
24 Vermeire S, Wild G, Kocher K, Cousineau J,
Dufresne L, Bitton A, Langelier D, Pare P,
Lapointe G, Cohen A, Daly MJ, Rioux JD:
CARD15 genetic variation in a Quebec popu-
lation: Prevalence, genotype-phenotype rela-
tionship, and haplotype structure. Am J Hum
Genet 2002;71:74–83.
25 Radlmayr M, Torok HP, Martin K, Folwaczny
C: The c-insertion mutation of the NOD2 gene
is associated with fistulizing and fibrostenotic
phenotypes in Crohn’s disease. Gastroenterol-
ogy 2002;122:2091–2092.
26 Bonen DK, Ogura Y, Nicolae DL, Inohara N,
Saab L, Tanabe T, Chen FF, Foster SJ, Duerr
RH, Brant SR, Cho JH, Nunez G: Crohn’s dis-
ease-associated NOD2 variants share a signal-
ing defect in response to lipopolysaccharide
and peptidoglycan. Gastroenterology 2003;
124:140–146.
27 Cavanaugh JA, Adams KE, Quak EJ, Bryce
ME, O’Callaghan NJ, Rodgers HJ, Magarry
GR, Butler WJ, Eaden JA, Roberts-Thomson
IC, Pavli P, Wilson SR, Callen DF: CARD15/
NOD2 risk alleles in the development of
Crohn’s disease in the Australian population.
Ann Hum Genet 2003;67:35–41.
28 Bairead E, Harmon DL, Curtis AM, Kelly Y,
O’Leary C, Gardner M, Leahy DT, Vaughan P,
Keegan D, O’Morain C, O’Donoghue D, Sha-
nahan F, Parfrey NA, Quane KA: Association
of NOD2 with Crohn’s disease in a homoge-
nous Irish population. Eur J Hum Genet 2003;
11:237–244.
29 Hugot JP, Laurent-Puig P, Gower-Rousseau C,
Olson JM, Lee JC, Beaugerie L, Naom I, Dupas
JL, Van Gossum A, Orholm M, Bonaiti-Pellie
C, Weissenbach J, Mathew CG, Lennard-Jones
JE, Cortot A, Colombel JF, Thomas G: Map-
ping of a susceptibility locus for Crohn’s dis-
ease on chromosome 16. Nature 1996;379:
821–823.
CARD15/NOD2 Mutations in Crohn’s
Disease
Dig Dis 2003;21:339–345 345
30 Cavanaugh J: IBD International Genetics Con-
sortium: International collaboration provides
convincing linkage replication in complex dis-
ease through analysis of a large pooled data set:
Crohn disease and chromosome 16. Am J Hum
Genet 2001;68:1165–1171. 
31 Ogura Y, Inohara N, Benito A, Chen FF, Ya-
maoka S, Nunez G: Nod2, a Nod1/Apaf-1
family member that is restricted to monocytes
and activates NF-kappaB. J Biol Chem 2001;
276:4812–4818. 
32 Bonen DK, Cho JH: The genetics of inflamma-
tory bowel disease. Gastroenterology 2003;124:
521–536.
33 Inoue N, Tamura K, Kinouchi Y, Fukuda Y,
Takahashi S, Ogura Y, Inohara N, Nunez G,
Kishi Y, Koike Y, Shimosegawa T, Shimoyama
T, Hibi T: Lack of common NOD2 variants in
Japanese patients with Crohn’s disease. Gas-
troenterology 2002;123:86–91.
34 Yamazaki K, Takazoe M, Tanaka T, Kazumori
T, Nakamura Y: Absence of mutation in the
NOD2/CARD15 gene among 483 Japanese pa-
tients with Crohn’s disease. J Hum Genet
2002;47:469–472.
35 Sugimura M, Kinouchi Y, Takahashi S, Aihara
H, Takagi S, Negoro K, Obana N, Kojima Y,
Matsumoto K, Kikuchi T, Hiroki M, Oomori
S, Shimosegawa T: CARD15/NOD2 mutation-
al analysis in Japanese patients with Crohn’s
disease. Clin Genet 2003;63:160–162.
36 Croucher PJ, Mascheretti S, Hampe J, Huse K,
Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK,
Krawczak M, Kim WH, Schreiber S: Haplo-
type structure and association to Crohn’s dis-
ease of CARD15 mutations in two ethnically
divergent populations. Eur J Hum Genet 2003;
11:6–16.
37 Leong RW, Armuzzi A, Ahmad T, Wong ML,
Tse P, Jewell DP, Sung JJ: NOD2/CARD15
gene polymorphisms and Crohn’s disease in
the Chinese population. Aliment Pharmacol
Ther 2003;17:1465–1470.
38 Bonen DK, Nicolae DL, Moran T, Turkyilmaz
MA, Ramos R, Karaliukas R, Brant SR, Duerr
RH, Kirschner BS, Hanauer SB, Cho JH: Ra-
cial Differences in NOD2 variation: Character-
ization of NOD2 in African-Americans with
Crohn’s disease. Gastroenterology 2002;122:A-
29.
39 Zhou Z, Lin XY, Akolkar PN, Gulwani-Akol-
kar B, Levine J, Katz S, Silver J: Variation at
NOD2/CARD15 in familial and sporadic cases
of Crohn’s disease in the Ashkenazi Jewish
population. Am J Gastroenterol 2002;97:
3095–3101.
40 Linde K, Boor PP, Houwing-Duistermaat JJ,
Kuipers EJ, Wilson JH, de Rooij FW: Card15
and Crohn’s disease: Healthy homozygous car-
riers of the 3020insC frameshift mutation. Am
J Gastroenterol 2003;98:613–617.
41 Inohara N, Ogura Y, Nunez G: Nods: A family
of cytosolic proteins that regulate the host re-
sponse to pathogens. Curr Opin Microbiol
2002;5:76–80.
42 Girardin SE, Sansonetti PJ, Philpott DJ: Intra-
cellular vs. extracellular recognition of patho-
gens-common concepts in mammals and flies.
Trends Microbiol 2002;10:193–199.
43 Gutierrez O, Pipaon C, Inohara N, Fontalba A,
Ogura Y, Prosper F, Nunez G, Fernandez-
Luna JL: Induction of Nod2 in myelomonocyt-
ic and intestinal epithelial cells via nuclear fac-
tor-kappa B activation. J Biol Chem 2002;277:
41701–41705.
44 Hisamatsu T, Suzuki M, Reinecker HC, Na-
deau WJ, McCormick BA, Podolsky DK:
CARD15/NOD2 functions as an antibacterial
factor in human intestinal epithelial cells. Gas-
troenterology 2003;124:993–1000.
45 Rosenstiel P, Fantini M, Brautigam K, Kuh-
bacher T, Waetzig GH, Seegert D, Schreiber S:
TNF-alpha and IFN-gamma regulate the ex-
pression of the NOD2 (CARD15) gene in hu-
man intestinal epithelial cells. Gastroenterol-
ogy 2003;12:1001–1009.
46 Berrebi D, Maudinas R, Hugot JP, Chamail-
lard M, Chareyre F, De Lagausie P, Yang C,
Desreumaux P, Giovannini M, Cezard JP,
Zouali H, Emilie D, Peuchmaur M: Card15
gene overexpression in mononuclear and epi-
thelial cells of the inflamed Crohn’s disease
colon. Gut 2003;52:840–846.
47 Lala S, Ogura Y, Osborne C, Hor SY, Brom-
field A, Davies S, Ogunbiyi O, Nunez G, Ke-
shav S: Crohn’s disease and the NOD2 gene: A
role for Paneth cells. Gastroenterology 2003;
125:47–57.
48 Chamaillard M, Philpott D, Girardin SE,
Zouali H, Lesage S, Chareyre F, Bui TH, Gio-
vannini M, Zaehringer U, Penard-Lacronique
V, Sansonetti PJ, Hugot JP, Thomas G: Gene-
environment interaction modulated by allelic
heterogeneity in inflammatory diseases. Proc
Natl Acad Sci USA 2003;100:3455–3460.
49 Inohara N, Ogura Y, Fontalba A, Gutierrez O,
Pons F, Crespo J, Fukase K, Inamura S, Kusu-
moto S, Hashimoto M, Foster SJ, Moran AP,
Fernandez-Luna JL, Nunez G: Host recogni-
tion of bacterial muramyl dipeptide mediated
through NOD2. Implications for Crohn’s dis-
ease. J Biol Chem 2003;278:5509–5512. 
50 Girardin SE, Boneca IG, Viala J, Chamaillard
M, Labigne A, Thomas G, Philpott DJ, Sanso-
netti PJ: Nod2 is a general sensor of peptidogly-
can through muramyl dipeptide (MDP) detec-
tion. J Biol Chem 2003;278:8869–8872.
51 Bouma G, Strober W: The immunological and
genetic basis of inflammatory bowel disease.
Nat Rev Immunol 2003;521–533.
52 Wehkamp J, Harder J, Weichental M, Herrlin-
ger KR, Schmidt M, Schlee M, Nuding S,
Schwab M, Schäfferle E, Stallmach A, Feller-
mann K, Schröder JM, Stange EF: Pathome-
chanismus des Morbus Crohn mit NOD-2
(CARD15) Mutation: Defiziente mukosale De-
fensinexpression bei intakter Zytokinexpres-
sion. Z Gastroenterol 2003;41:A741.
53 Hugot JP, Zouali H, Lesage S: Lessons to be
learned from the NOD2 gene in Crohn’s dis-
ease. Eur J Gastroenterol Hepatol 2003;15:
593–597.
54 Gasche C, Alizadeh BZ, Pena AS: Genotype-
phenotype correlations: How many disorders
constitute inflammatory bowel disease? Eur J
Gastroenterol Hepatol 2003;15:599–606.
55 Lee JC, Lennard-Jones JE: Inflammatory bow-
el disease in 67 families each with three or
more affected first-degree relatives. Gastroen-
terology 1996;111:587–596.
56 Bayless TM, Tokayer AZ, Polito JM 2nd,
Quaskey SA, Mellits ED, Harris ML: Crohn’s
disease: Concordance for site and clinical type
in affected family members – Potential heredi-
tary influences. Gastroenterology 1996;111:
573–579.
57 Hampe J, Grebe J, Nikolaus S, Solberg C,
Croucher PJ, Mascheretti S, Jahnsen J, Moum
B, Klump B, Krawczak M, Mirza MM, Foelsch
UR, Vatn M, Schreiber S: Association of
NOD2 (CARD 15) genotype with clinical
course of Crohn’s disease: A cohort study. Lan-
cet 2002;359:1661–1665.
58 Helio T, Halme L, Lappalainen M, Fodstad H,
Paavola-Sakki P, Turunen U, Farkkila M, Kru-
sius T, Kontula K: CARD15/NOD2 gene vari-
ants are associated with familially occurring
and complicated forms of Crohn’s disease. Gut
2003;52:558–562.
59 Abreu MT, Taylor KD, Lin YC, Hang T,
Gaiennie J, Landers CJ, Vasiliauskas EA, Kam
LY, Rojany M, Papadakis KA, Rotter JI, Tar-
gan SR, Yang H: Mutations in NOD2 are asso-
ciated with fibrostenosing disease in patients
with Crohn’s disease. Gastroenterology 2002;
123:679–688.
60 Louis E, Michel V, Hugot JP, Reenaers C, Fon-
taine F, Delforge M, El Yafi F, Colombel JF,
Belaiche J: Early development of stricturing or
penetrating pattern in Crohn’s disease is in-
fluenced by disease location, number of flares,
and smoking but not by NOD2/CARD15 geno-
type. Gut 2003;52:552–557.
61 Fidder HH, Olschwang S, Avidan B, Zouali H,
Lang A, Bardan E, Picard O, Bar-Meir S, Co-
lombel JF, Chowers Y: Association between
mutations in the CARD15 (NOD2) gene and
Crohn’s disease in Israeli Jewish patients. Am J
Med Genet 2003;121:240–244.
62 Vermeire S, Louis E, Rutgeerts P, De Vos M,
Van Gossum A, Belaiche J, Pescatore P, Fiasse
R, Pelckmans P, Vlietinck R, Merlin F, Zouali
H, Thomas G, Colombel JF, Hugot JP: Belgian
Group of Infliximab Expanded Access Pro-
gram and Fondation Jean Dausset CEPH, Par-
is, France: NOD2/CARD15 does not influence
response to infliximab in Crohn’s disease. Gas-
troenterology 2002;123:106–111.
63 Mascheretti S, Hampe J, Croucher PJ, Niko-
laus S, Andus T, Schubert S, Olson A, Bao W,
Fölsch UR, Schreiber S: Response to inflixi-
mab treatment in Crohn’s disease is not associ-
ated with mutations in the CARD15 (NOD2)
gene: An analysis in 534 patients from two mul-
ticenter, prospective GCP-level trials. Pharma-
cogenetics 2002;12:509–515.
64 Sartor RB: Clinical applications of advances in
the genetics of IBD. Rev Gastroenterol Disord
2003;3(suppl 1):S9–S17.
65 Folwaczny C, Glas J, Torok HP: Crohn’s dis-
ease: An immunodeficiency? Eur J Gastroen-
terol Hepatol 2003;15:621–626.
